Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.03, $0.11 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $52.2 million versus the consensus estimate of $42.06 million.

GUIDANCE:

Halozyme Therapeutics sees FY2016 revenue of $110-125 million, versus the consensus of $120.2 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.